+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psoriasis Biosimilar Market - Global Forecast 2026-2032- Product Image
Psoriasis Biosimilar Market - Global Forecast 2026-2032- Product Image
Sale

Psoriasis Biosimilar Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127111
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Psoriasis Biosimilar Market is projected to reach USD 9.74 Billion in 2026. It is expected to continue growing at a CAGR of 11.22%, reaching USD 18.88 Billion by 2032.

Psoriasis Biosimilars: Executive Overview

Psoriasis biosimilars are biologic medicines developed to demonstrate high similarity to an approved reference biologic, with no clinically meaningful differences in quality, safety, or efficacy. Their relevance is strongest in moderate-to-severe disease, where biologic treatment can substantially improve disease control and quality of life. Adoption depends on regulatory authorization, interchangeability rules, prescriber confidence, patient support, reimbursement, tendering, and evidence generated through routine use.

How Biosimilars Are Reshaping Psoriasis Care

The psoriasis treatment landscape is shifting from a limited set of originator biologics toward broader biologic choice and more active competition after loss of exclusivity. Regulatory pathways increasingly emphasize analytical comparability, pharmacokinetic evidence, immunogenicity assessment, and targeted clinical confirmation rather than repeating every originator trial. This can support more efficient development while maintaining clinical standards. Practical adoption still varies because substitution policies, formulary controls, tender practices, and education differ across health systems.

Artificial Intelligence Across Biosimilar Development and Delivery

Artificial intelligence can support psoriasis biosimilar programs by improving molecule and process characterization, detecting manufacturing deviations, prioritizing quality investigations, and identifying patterns in pharmacovigilance data. In clinical practice, machine-learning tools may help stratify patients, monitor treatment response, and identify adherence risks using structured records and patient-reported outcomes. These applications require validated datasets, explainable outputs, cybersecurity controls, and human oversight. AI can improve efficiency, but it does not replace regulatory comparability evidence or clinician judgment.

Regional Differences in Access and Adoption

North America is shaped by complex reimbursement, pharmacy-benefit, interchangeability, and payer-management arrangements, while Latin America often combines expanding biologic access with uneven regulatory capacity and public procurement structures. Europe has extensive experience with biosimilar regulation and institutional purchasing, although national substitution and reimbursement policies remain distinct. The Middle East is influenced by centralized procurement, local manufacturing ambitions, and differences in specialist access. Africa faces constraints involving affordability, supply continuity, diagnostic capacity, and biologic infrastructure. Asia-Pacific presents substantial diversity, ranging from mature regulatory and hospital systems to rapidly developing access pathways, with local evidence and manufacturing playing important roles.

Group-Level Policy and Access Dynamics

ASEAN markets differ in regulatory maturity, reimbursement design, and dependence on public hospitals, making regional alignment valuable but difficult. BRICS members show varied approaches to domestic production, procurement, and biologic regulation, with access shaped by national health priorities. The European Union benefits from a shared scientific regulatory framework but retains important national differences in pricing, substitution, and reimbursement. G7 health systems generally combine strong regulatory oversight with sophisticated payer and pharmacovigilance requirements. GCC countries often use centralized purchasing and coordinated health policies, while NATO members remain a heterogeneous group whose psoriasis access is determined primarily by national health systems rather than alliance membership.

Country-Level Signals for Market Participation

Australia and Canada combine established biologic oversight with public reimbursement processes that can influence switching and formulary placement. Brazil, Mexico, India, China, and Russia are shaped by domestic manufacturing, procurement policy, and differing regulatory pathways, while access can vary substantially between urban and underserved settings. France, Germany, Italy, Spain, and the United Kingdom operate within mature European evidence and reimbursement environments, but prescribing, tendering, and substitution practices differ by jurisdiction. Japan and South Korea maintain advanced regulatory and clinical infrastructures, with local requirements and payer decisions influencing uptake. The United States remains highly dependent on payer contracting, pharmacy distribution, interchangeability status, and clinician and patient confidence.

Priorities for Leaders in Psoriasis Biosimilars

Industry leaders should build evidence plans around the requirements of each jurisdiction, including analytical comparability, immunogenicity, switching, real-world outcomes, and pharmacovigilance. Access strategies should align with hospital tenders, specialty distribution, payer evidence needs, and patient-support expectations rather than relying on price alone. Manufacturing resilience requires qualified backup suppliers, rigorous process controls, cold-chain visibility, and continuity planning. Clear education for dermatologists, pharmacists, nurses, and patients can address misconceptions about biosimilarity and switching. Leaders should also establish governance for responsible AI, including data quality controls, validation, privacy protection, and documented human review.

Evidence-Based Research Methodology

This executive summary uses a structured review framework for psoriasis biosimilars, focusing on publicly established regulatory principles, clinical-development practices, health-system access mechanisms, pharmacovigilance requirements, and regional policy differences. The assessment organizes findings across the specified regions, country groups, and countries, while separating scientific comparability from commercial and reimbursement considerations. Because no underlying study set or country-level dataset was supplied, the summary avoids quantitative claims and does not infer market size, shares, or forecasts. Findings should be validated against current regulatory decisions, formularies, procurement records, and peer-reviewed clinical evidence before operational use.

Building Sustainable Confidence in Psoriasis Biosimilars

Psoriasis biosimilars can broaden biologic choice and support more sustainable treatment systems when scientific evidence is paired with reliable supply, transparent reimbursement, and informed clinical decision-making. Adoption will remain uneven unless stakeholders address national substitution rules, patient communication, manufacturing resilience, and post-market monitoring. The strongest strategies combine jurisdiction-specific regulatory planning with measurable quality standards, responsible digital tools, and continuous evidence generation. Success ultimately depends on maintaining confidence that affordability and competition are achieved without compromising patient outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Psoriasis Biosimilar Market, by Product Type
7.1. Introduction
7.2. Fusion Proteins
7.3. Monoclonal Antibodies
7.3.1. Adalimumab Biosimilars
7.3.2. Infliximab Biosimilars
8. Psoriasis Biosimilar Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous Administration
8.3. Subcutaneous Administration
9. Psoriasis Biosimilar Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Psoriasis Biosimilar Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Dermatology Centers
11. Psoriasis Biosimilar Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Psoriasis Biosimilar Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Psoriasis Biosimilar Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Amgen Inc.
15.2. Biocon Ltd.
15.3. Boehringer Ingelheim International GmbH
15.4. Celltrion, Inc.
15.5. Coherus BioSciences, Inc.
15.6. Fresenius Kabi
15.7. Pfizer Inc.
15.8. Samsung Bioepis Co., Ltd.
15.9. Sandoz International GmbH
15.10. Stada Arzneimittel AG
15.11. Viatris, Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Psoriasis Biosimilar Market, Years Considered for the Study
FIGURE 2. Global Psoriasis Biosimilar Market, Research Design
FIGURE 3. Global Psoriasis Biosimilar Market, Research Framework
FIGURE 4. Global Psoriasis Biosimilar Market, Data Triangulation
FIGURE 5. Global Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Psoriasis Biosimilar Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Psoriasis Biosimilar Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Psoriasis Biosimilar Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Psoriasis Biosimilar Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Psoriasis Biosimilar Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Psoriasis Biosimilar Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Psoriasis Biosimilar Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Psoriasis Biosimilar Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Psoriasis Biosimilar Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Psoriasis Biosimilar Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Psoriasis Biosimilar Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Psoriasis Biosimilar Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Psoriasis Biosimilar Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Psoriasis Biosimilar Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Psoriasis Biosimilar Market Segmentation & Coverage
TABLE 2. Global Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 3. Global Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Fusion Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Fusion Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Fusion Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Adalimumab Biosimilars Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Adalimumab Biosimilars Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Adalimumab Biosimilars Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Infliximab Biosimilars Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Infliximab Biosimilars Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Infliximab Biosimilars Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Subcutaneous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 24. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 34. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Specialty Dermatology Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Specialty Dermatology Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Specialty Dermatology Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Asia-Pacific Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 47. Asia-Pacific Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 50. North America Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. North America Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 52. North America Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 53. North America Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 54. North America Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 55. North America Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 56. Latin America Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Latin America Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 58. Latin America Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 59. Latin America Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 60. Latin America Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 61. Latin America Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. Europe Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Europe Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 64. Europe Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 65. Europe Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 66. Europe Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. Europe Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Middle East Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Middle East Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. Middle East Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 71. Middle East Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 72. Middle East Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Middle East Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Africa Psoriasis Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Africa Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. Africa Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 77. Africa Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. Africa Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. Africa Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Global Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. ASEAN Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. ASEAN Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 83. ASEAN Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 84. ASEAN Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. ASEAN Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. ASEAN Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. GCC Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. GCC Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 89. GCC Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 90. GCC Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 91. GCC Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. GCC Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. European Union Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. European Union Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. European Union Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 96. European Union Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. European Union Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. European Union Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. BRICS Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. BRICS Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. BRICS Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 102. BRICS Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. BRICS Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. BRICS Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. G7 Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. G7 Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. G7 Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 108. G7 Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. G7 Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. G7 Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. NATO Psoriasis Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. NATO Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. NATO Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 114. NATO Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. NATO Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. NATO Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Global Psoriasis Biosimilar Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. United States Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 119. United States Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. United States Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 121. United States Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. United States Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. United States Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. Canada Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 125. Canada Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 126. Canada Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 127. Canada Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. Canada Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Canada Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Mexico Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 131. Mexico Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. Mexico Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 133. Mexico Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. Mexico Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. Mexico Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Brazil Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 137. Brazil Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. Brazil Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 139. Brazil Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 140. Brazil Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Brazil Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. United Kingdom Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 143. United Kingdom Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. United Kingdom Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 145. United Kingdom Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. United Kingdom Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. United Kingdom Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Germany Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 149. Germany Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 150. Germany Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 151. Germany Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. Germany Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Germany Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. France Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 155. France Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. France Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 157. France Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. France Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. France Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Russia Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 161. Russia Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. Russia Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 163. Russia Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Russia Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. Russia Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. Italy Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 167. Italy Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. Italy Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 169. Italy Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. Italy Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Italy Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Spain Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 173. Spain Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 174. Spain Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 175. Spain Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. Spain Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Spain Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. China Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 179. China Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. China Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 181. China Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. China Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. China Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. India Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 185. India Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. India Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 187. India Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. India Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. India Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Japan Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 191. Japan Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. Japan Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 193. Japan Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. Japan Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. Japan Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Australia Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 197. Australia Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Australia Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 199. Australia Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 200. Australia Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Australia Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. South Korea Psoriasis Biosimilar Market Size, 2017-2032 (USD Million)
TABLE 203. South Korea Psoriasis Biosimilar Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. South Korea Psoriasis Biosimilar Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 205. South Korea Psoriasis Biosimilar Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. South Korea Psoriasis Biosimilar Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. South Korea Psoriasis Biosimilar Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Global Psoriasis Biosimilar Market Share, by Key Player, 2025
TABLE 209. Global Psoriasis Biosimilar Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Stada Arzneimittel AG
  • Viatris, Inc.

Related Topics

Related Reports

Psoriasis Biosimilars Market Report 2026 - Product Image

Psoriasis Biosimilars Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Psoriasis Treatment Market - Global Forecast 2026-2032 - Product Image

Psoriasis Treatment Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Biosimilars Market - Global Forecast 2026-2032 - Product Image

Biosimilars Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Psoriasis Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Psoriasis Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Global Psoriasis Treatment Market Outlook, 2031 - Product Image

Global Psoriasis Treatment Market Outlook, 2031

  • Report
  • 209 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.